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The phenanthrene-derivative 9-phenanthrol is a recently identified inhibitor of the transient receptor potential melastatin
(TRPM) 4 channel, a Ca2+-activated non-selective cation channel whose mechanism of action remains to be determined.
Subsequent studies performed on other ion channels confirm the specificity of the drug for TRPM4. In addition,
9-phenanthrol modulates a variety of physiological processes through TRPM4 current inhibition and thus exerts beneficial
effects in several pathological conditions. 9-Phenanthrol modulates smooth muscle contraction in bladder and cerebral
arteries, affects spontaneous activity in neurons and in the heart, and reduces lipopolysaccharide-induced cell death. Among
promising potential applications, 9-phenanthrol exerts cardioprotective effects against ischaemia-reperfusion injuries and
reduces ischaemic stroke injuries. In addition to reviewing the biophysical effects of 9-phenanthrol, here we present
information about its appropriate use in physiological studies and possible clinical applications.
Abbreviations
ABC, ATP binding cassette; AGS cells, human gastric adenocarcinoma cell line; BKCa, large conductance Ca2+-activated
K+ current; CFTR, cystic fibrosis transmembrane conductance regulator; DSM, detrusor smooth muscle; EADs, early after
depolarizations; H-89, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamidedihydrochloride hydrate; HCN,
hyperpolarization and cyclic nucleotide gated channel; ICa,L, L-type Ca2+ current; IK, delayed outward rectifyer K+ current;
KATP, ATP sensitive K+ channel; KIR, inward rectifier K+ current; KV, voltage-gated K+ current; MKN-45 cells, human gastric
cancer cell line; MPB-104, 5-butyl-7-chloro-6-hydroxybenzo[c]quinolizinium chloride; NSCCa, Ca2+-activated
non-selective cation channels; SUR, sulfonylurea receptor; TRP, transient receptor potential channels; TRPC, transient
receptor potential canonical; TRPM, transient receptor potential melastatin
Introduction
9-Phenanthrol, also called 9-hydroxyphenanthrene or
phenanthrene-9-ol in the IUPAC (International Union of
Pure and Applied Chemistry) nomenclature, has been known
for more than a century (Pschorr and Schroter, 1902;
Moriconi et al., 1959). It is a benzo[c]quinolizinium deriva-
tive composed of three fused benzene rings (Figure 1).
Despite primary results indicating fungitoxicity of the mol-
ecule (Rich and Horsfall, 1954), it was, until recently, only
used as a biomarker of anthropogenic compound pollution.
Indeed, 9-phenanthrol may originate from other hydrox-
ylated polycyclic aromatic hydrocarbons (PAH). Those mol-
ecules come from incomplete combustion of organic matter,
resulting, in part, from human activities. PAHs found in pol-
luted soil or water can be ingested by organisms like fish. One
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of these, the phenanthrene, is partly metabolized to form
molecules such as 9-phenanthrol, which can become concen-
trated in tissues because of its hydrophobicity (Escartin and
Porte, 1999; Koenig et al., 2013). As PAHs such as phenan-
threne are highly toxic, 9-phenanthrol may be applicable for
depollution processes because it has a lower toxicity and can
be produced after phenanthrene biodegradation by proteo-
bacteria (Feng et al., 2012).
Far from these environmental concerns, we observed in
2008 that 9-phenanthrol inhibits the transient receptor
potential melastatin (TRPM) 4 channel (Grand et al., 2008).
TRPM4 forms a Ca2+-activated non-selective cation (NSCCa)
channel widely expressed in tissues from several mammalian
species including humans (Launay et al., 2002). The physi-
ological roles for the TRPM4 channel were difficult to identify
until the development of knockout mice and appropriate
pharmacological tools (Guinamard et al., 2011). Regarding
pharmacology, it has been confirmed that 9-phenanthrol spe-
cifically targets the TRPM4 channel (Table 1) and its use in a
variety of biological preparations has unmasked the contri-
butions of the TRPM4 channel in physiological processes.
Here we review 9-phenanthrol as a TRPM4 channel
inhibitor. We summarize the identification of 9-phenanthrol
and document its specificity among ion channels. Further, we
review physiological processes modulated by 9-phenanthrol
and recommend appropriate applications of the drug, while
acknowledging their caveats and limitations.
Looking for TRPM4 channel
pharmacological inhibitors
The TRPM4 channel belongs to the transient receptor poten-
tial (TRP) protein family, whose members form non-selective
cation channels (Alexander et al., 2013). It shares with its
closest relative, the TRPM5 channel, a lack of selectivity for
monovalent cations (i.e. equal permeability for Na+ and K+),
and while these channels are Ca2+ impermeable their activa-
tion mechanism is simultaneously sensitive to internal Ca2+
concentration (Launay et al., 2002; Guinamard et al., 2011).
In addition, both channels have a higher activity at depolar-
ized voltages. Such NSCCa currents were recognized in native
preparations from a variety of tissues (Teulon, 2000).
Unmasking their physiological roles has depended on
pharmacological tools. Several pharmacological agents
inhibit TRPM4 channels and NSCCa currents more generally
(Figure 1). The most commonly used NSCCa channel inhibitor
is the non-steroidal anti-inflammatory drug flufenamic acid
Figure 1
Chemical structures of pharmacological inhibitors of TRPM4 (9-phenanthrol, MPB-104, flufenamic acid, glibenclamide, quinine, quinidine) and
NSCCa currents (DPC, DCDPC, NPPB). Under each compound, arrows indicate its other main targets among ion channels, in addition to TRPM4
and NSCCa currents. The list indicates typical targets, but is not exhaustive.
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that inhibits both TRPM4 and TRPM5 channels (Ullrich et al.,
2005). This molecule is advantageous because it rapidly
affects channel activity and is reversible. However, it has a
large spectrum of targets, particularly among ion channels
(Guinamard et al., 2013). The bitter compound quinine and
its stereoisomer quinidine similarly inhibit TRPM4 and
TRPM5 channels (Talavera et al., 2008), but once again are
not specific (White, 2007). Spermine is another NSCCa antago-
nist without specificity for underlying channel type (Nilius
et al., 2004). The sulfonylurea glibenclamide was shown to
inhibit native NSCCa currents and the TRPM4 channel
(Demion et al., 2007), but it is also known to interact with
other channels, mainly those belonging to the ATP binding
cassette (ABC) protein family and the ATP-dependent K+
channel, which is a multimer of inwardly rectifying K+
channel subunits and the sulfonylurea receptor (SUR;
Alexander et al., 2013). Note that the co-assembly of the
TRPM4 channel with the SUR1, such as occurs in acute CNS
injuries, potentiates its sensitivity to glibenclamide (Woo
et al., 2013b). TRPM4-like currents are also inhibited by the
closely related chloride channel blockers diphenylamine-2-
carboxylic acid, 3′,5′-dichlorodiphenylamine-2-carboxylic
acid and 5-nitro-2-(3-phenylpropyl-amino)-benzoic acid in a
variety of tissues (Gögelein and Pfannmüller, 1989; Chraïbi
et al., 1994; Teulon, 2000). Even though all of these molecules
target the TRPM4 channel, none is a specific antagonist.
Moreover, except for the presence of phenol rings, they share
few (if any) chemical determinants (Figure 1).
Looking for new candidates to inhibit the TRPM4
channel, we were intrigued by several similarities between
TRPM4 and ABC proteins. Both are sensitive to ATP and hold
ATP binding sites within their amino acid sequence (Ullrich
et al., 2005; Frelet and Klein, 2006). In addition, as referenced
earlier, the antidiabetic sulfonylurea glibenclamide modu-
lates the TRPM4 channel (Demion et al., 2007) as well as ABC
proteins including SURs and the cystic fibrosis transmem-
brane conductance regulator (CFTR) chloride channel
(Sheppard and Welsh, 1992; Frelet and Klein, 2006). We
hypothesized that other modulators of ABC proteins might
also affect the TRPM4 channel. Indeed this proved correct
for the CFTR activator 5-butyl-7-chloro-6-hydroxybenzo[c]-
quinolizinium chloride (MPB-104) (Figure 1), which inhibits
the TRPM4 channel with an IC50 of ∼2 × 10−5 mol·L−1 (Grand
et al., 2008). However, MPB-104 is not specific for the TRPM4
channel, as it also modulates the CFTR channel. Therefore,
in searching for other related compounds, we tested
9-phenanthrol (Figure 1), which lacks several components
necessary for CFTR channel activation. As expected,
9-phenanthrol did not modulate the CFTR channel, yet it
inhibited TRPM4 channels heterologously expressed in HEK-
293 cells (Grand et al., 2008).
Inhibition of recombinant TRPM4 channel
by 9-phenanthrol
As mentioned earlier, and shown in concentration–response
curves (Figure 2), 9-phenanthrol inhibited human TRPM4
channel activity in patch recordings from transfected HEK-
293 cells (Grand et al., 2008). In the conventional whole-cell
configuration, superfusion of 9-phenanthrol in the bath
inhibited the TRPM4-mediated current with an IC50 of
1.7 × 10−5 mol·L−1 (Table 1). The inhibition was also observed
in nystatin perforated whole-cell membrane currents from
TRPM4-transfected COS-7 cells (Woo et al., 2013a). Similar
results were observed in the inside-out configuration (Grand
et al., 2008; Woo et al., 2013a). These data indicate that the
molecule may interact with the channel on both sides, or
more likely, that the molecule is able to cross the membrane
because of its hydrophobicity. The interaction site of
9-phenanthrol within the channel structure is not known.
However, the glycosylation state of the protein is not
involved. Indeed, the N988Q substitution, at an extracellular
location near the pore-forming loop between the transmem-
brane segments 5 and 6, which results in the disappearance of
the N-glycosylated forms of the protein, did not modify its
inhibition by 9-phenanthrol (Woo et al., 2013a). Because
channel inhibition occurs within seconds in the inside-out
configuration, but within a minute in the whole-cell configu-
ration, a reasonable starting assumption is that 9-phenanthrol
interacts with the TRPM4 channel intracellularly.
The Hill coefficient of the concentration–response curve
is close to 1, indicating no cooperation in 9-phenanthrol
interactions with the channel. The concentration–response
curves performed in the inside-out configuration at positive
and negative voltages showed no evidence of voltage-
dependent inhibition (Grand et al., 2008).
Whether recorded in inside-out patches or the whole-cell
configuration, TRPM4 channel inhibition by 9-phenanthrol
is reversible, even though complete recovery can take several
minutes after channel exposure to high concentrations
(∼10−4 mol·L−1).
Table 1
Effect of 9-phenanthrol on recombinant ion channels
Current Model Effect Concentration in mol·L−1 References
TRPM4 HEK-293 Inhibition IC50 = 1.7 × 10−5 Grand et al., 2008
TRPM5 HEK-293 None 10−4 Grand et al., 2008
TRPC3 HEK-293 None 3 × 10−5 Gonzales et al., 2010b
TRPC6 HEK-293 None 3 × 10−5 Gonzales et al., 2010b
CFTR CHO None 2.5 × 10−4 Grand et al., 2008
When known, the IC50 is presented, otherwise, the highest concentration tested is indicated.
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Inhibition of endogenous TRPM4 currents
by 9-phenanthrol
After its identification as a recombinant TRPM4 channel
inhibitor, the effects of 9-phenanthrol were tested on endog-
enous TRPM4-like currents from several native tissues
(Table 2).
The TRPM4 channel is highly expressed in epithelia such
as kidney. HEK-293 cells obtained from this type of tissue
weakly express an endogenous TRPM4-like current, which is
inhibited by 80% by 10−4 mol·L−1 9-phenanthrol in whole-cell
recordings (Amarouch et al., 2013).
The TRPM4 channel is also expressed in various smooth
muscles cells (Earley, 2013). A TRPM4-like transient inward
current is attenuated by 9-phenanthrol with an IC50 of
1 × 10−5 mol·L−1 in perforated patches, and totally inhibited
by 3 × 10−5 mol·L−1 in whole-cell recordings from rat cerebral
artery smooth muscle cells (Gonzales et al., 2010b; Gonzales
and Earley, 2012). 9-Phenanthrol, at 3 × 10−5 mol·L−1, inhibits
40% of the same current during perforated-patch recordings
from guinea pig and rat detrusor smooth muscle (DSM) cells
(Parajuli et al., 2013; Smith et al., 2013a,b). In addition,
10−4 mol·L−1 9-phenanthrol attenuates TRPM4-like currents in
inside-out patch recordings from monkey colonic smooth
muscle cells (Dwyer et al., 2011).
We have reported the functional expression of TRPM4
channels in cardiomyocytes, including human cardiac tissue
(Guinamard et al., 2004; Simard et al., 2013). Endogenous
TRPM4 channel activity in inside-out patch recordings from
mouse isolated atrial cardiomyocytes was inhibited by 80% in
response to 10−5 mol·L−1 9-phenanthrol (Simard et al., 2013).
Purkinje cells from mouse cerebellum express a calcium-
dependent depolarization-induced slow current whose prop-
erties match those of TRPM4 and TRPM5 channels (Kim et al.,
2013). The current is smaller in Trpm4 null mice, but is
not affected in Trpm5 null mice, which indicates that the
calcium-dependent inward current probably corresponds
to a TRPM4 current. This current is totally abolished by
10−5 mol·L−1 9-phenanthrol (Kim et al., 2013).
The effects of 9-phenanthrol were also tested on TRPM4-
like endogenous currents in two human gastric adenocarci-
noma cell lines, AGS and MKN-45. In both cell types,
3 × 10−5 mol·L−1 9-phenanthrol reduced the current by 90%
(Kim et al., 2012).
9-phenanthrol effects on other ion channels
To evaluate specificity of 9-phenanthrol for the TRPM4
channel, its effects were also tested on other recombinant ion
channels as well as native currents (Tables 1 and 2). Concen-
trations at or exceeding 3 × 10−5 mol·L−1 were used in all
cases. Note that 9-phenanthrol concentrations greater than
10−4 mol·L−1 may be difficult to test precisely because the
molecule partly precipitates at such levels even if dissolved in
DMSO.
9-Phenanthrol was tested on several members of the TRP
channel family responsible for a large variety of non-selective
cationic currents. First of all, it was tested on the TRPM5
channel, the closest TRPM4 relative within the family. A
recombinant TRPM5 current was not affected by 10−4 mol·L−1
9-phenanthrol in HEK-293 cells, which is an encouraging
sign regarding its high selectivity for the TRPM4 channel
(Grand et al., 2008). This lack of effect on the TRPM5 channel
was confirmed in a preparation of isolated lingual taste cells
from mouse, which exhibit native NSCCa activated by linoleic
acid. This NSCCa current was abolished by Trpm5 gene
disruption or application of the TRPM5 channel-specific
inhibitor triphenylphosphine oxide, but not by 10−4 mol·L−1
9-phenanthrol (Liu et al., 2011). These data substantiate the
effectiveness of 9-phenanthrol at discriminating TRPM4 from
TRPM5 currents in native cells, which is challenging because
TRPM4 and TRPM5 channels share biophysical and regula-
Figure 2
TRPM4 channel inhibition by 9-phenanthrol. Effect of 9-phenanthrol on TRPM4 currents after recombinant expression of the human TRPM4 gene
in HEK-293 cells. (A) Concentration–response curve for the effects of 9-phenanthrol in the inside-out configuration (green squares) or whole-cell
configuration (red circles). Fitting the Hill equation to the data points indicates a similar IC50 at 2 × 10−5 mol·L−1 and a Hill coefficient close to 1.
The chemical structure of 9-phenanthrol is provided on the right. (B) Effect of 10−4 mol·L−1 9-phenanthrol applied to the inside of the membrane,
on a representative current recording in the inside-out configuration (Vm = +40 mV). Around 80 channels were present in the patch. (C) Effect of
10−4 mol·L−1 9-phenanthrol applied to the outside of the membrane, on a representative whole-cell recording. The voltage command is a ramp
from Vm = −100 to +100 mV. Note that the effects of 9-phenanthrol are reversible. See Grand et al. (2008) for protocol.
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tory properties as well as sensitivity to intracellular Ca2+ yet
lack of Ca2+ permeability, as mentioned earlier (Guinamard
et al., 2011). It is interesting to note that the main difference
between TRPM4 and TRPM5 channels is ATP sensitivity;
TRPM4 is blocked by internal ATP, while TRPM5 is not
(Ullrich et al., 2005). This discrepancy is probably due to the
presence of only one ATP binding site within the TRPM5
channel that appears to be inaccessible, while TRPM4
channel possesses four ATP binding sites (Ullrich et al., 2005).
This disparity between TRPM4 and TRPM5 might provide
some insights into the mechanism(s) involved in selective
TRPM4 inhibition by 9-phenanthrol.
Thirty micromolar 9-phenanthrol did not modulate
transient receptor potential canonical (TRPC) 3 or TRPC6
currents after recombinant expression in HEK-293 cells
(Gonzales et al., 2010b). This lack of effect is important
because TRPC3 and TRPC6 channels often co-express with
the TRPM4 channel, particularly in cardiac and smooth
muscle preparations.
In addition to non-selective cation channels, 9-
phenanthrol was tested on two recombinant chloride chan-
nels. Firstly, the effects of 9-phenanthrol were assessed via
radioactive iodide efflux on recombinant CFTR Cl– channel in
CHO cells. Even at 2.5 × 10−4 mol·L−1, 9-phenanthrol had no
effect (Grand et al., 2008). Once again, TRPM4 and CFTR may
be expressed in the same tissue. Secondly, an inhibitory effect
of 9-phenanthrol on recombinant TMEM16A channels
expressed in HEK-293 was reported in a recent abstract (Burris
et al., 2013), but the results have not yet been scrutinized.
However, pharmacological parity with TRPM4 is conceivable,
because the TMEM16A channel also supports a Ca2+-activated
chloride current (Terashima et al., 2013) and is widely
Table 2
Effects of 9-phenanthrol on endogenous currents
Current Model Effect
Concentration
in mol.L−1 References
TRPM4-like HEK-293 Inhibition 80% 10−4 Amarouch et al., 2013
TRPM4-like transient
inward
Rat cerebral arteries smooth muscle
cells
Inhibition IC50 = 10−5 Gonzales et al., 2010b
TRPM4-like transient
inward
Monkey colonic smooth muscle cells Inhibition 80% 10−4 Dwyer et al., 2011
TRPM4-like transient
inward
Rat, guinea pig DSM cells Inhibition 40% 3 × 10−5 Parajuli et al., 2013; Smith
et al., 2013a,b
TRPM4-like Mouse atrial cardiomyocytes Inhibition 80% 10−5 Simard et al., 2013
TRPM4-like Human adenocarcinoma AGS cells Inhibition 90% 3 × 10−5 Kim et al., 2012
TRPM4-like Human adenocarcinoma MKN-45
cells
Inhibition 90% 3 × 10−5 Kim et al., 2012
TRPM4-like depolarization-
induced slow
Mouse Purkinje cells from cerebellar
slices
Inhibition 100% 10−4 Kim et al., 2013
TRPM5-like Mouse tongue taste cells None 10−4 Liu et al., 2011
TRPM7-like Human adenocarcinoma AGS cells None 3 × 10−5 Kim et al., 2012
TRPM7-like Human adenocarcinoma MKN-45
cells
None 3 × 10−5 Kim et al., 2012
TRPM7-like Mouse intestinal cells of Cajal None 3 × 10−5 Kim et al., 2011
Voltage-dependent K+ Rat cerebral arteries smooth muscle
cells
None 3 × 10−5 Gonzales et al., 2010b
BKCa Rat cerebral arteries smooth muscle
cells
None 3 × 10−5 Gonzales et al., 2010b
KIR Rat cerebral arteries smooth muscle
cells
None 3 × 10−5 Gonzales et al., 2010b
Kv Rat cerebral arteries smooth muscle
cells
None 3 × 10−5 Gonzales et al., 2010b
ICa,L Rat cerebral arteries smooth muscle
cells
None 3 × 10−5 Gonzales et al., 2010b
ICa,L Rat ventricular cardiomyocyte None Inhibition 50% 10−5
10−4
Simard et al., 2012a
IK Rat ventricular cardiomyocyte None Inhibition 40% 10−5
10−4
Simard et al., 2012a
When known, the IC50 is presented, otherwise, the concentration tested is indicated with the corresponding % of inhibition.
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co-expressed with the TRPM4 channel in smooth muscle cells
(Bulley and Jaggar, 2013).
9-Phenanthrol was tested on several native ionic currents
with properties different from TRPM4 current. A TRPM7-like
endogenous current from human gastric adenocarcinoma cell
lines AGS and MKN-45 was found to be insensitive to
3 × 10−5 mol·L−1 9-phenanthrol (Kim et al., 2012) as was a
similar current from mouse interstitial cells of Cajal (Kim
et al., 2011).
In cerebral artery smooth muscle cells from rats, neither
voltage-gated K+ currents (KV), large conductance Ca2+-
activated K+ currents (BKCa), inward rectifyer K+ currents (KIR),
nor L-type Ca2+ currents (ICa,L) were modulated by
3 × 10−5 mol·L−1 9-phenanthrol (Gonzales et al., 2010b).
However, it is more likely that higher concentrations of the
drug are needed to have an effect on these channels. Indeed,
as reported in mouse isolated ventricular cardiomyocytes,
10−5 mol·L−1 9-phenanthrol has no effect on any of these
currents, but 10−4 mol·L−1 9-phenanthrol partially inhibits
L-type Ca2+ currents and the delayed outward rectifier K+
current (IK) (Simard et al., 2012a).
In dopamine neurons of the substantia nigra from mice
that expressed both TRPM4 and hyperpolarization and cyclic
nucleotide-gated (HCN) channels (which gives rise to
hyperpolarization-activated mixed cation current Ih in
neurons), 10−4 mol·L−1 9-phenanthrol and the HCN channel
blocker ZD7288 have distinct effects on rhythmic neuronal
activity (Mrejeru et al., 2011). While indirect, these data
suggest that 9-phenanthrol, even at high concentrations,
does not affect HCN channels.
To be exhaustive, even if it is not in the field of ion
channels, we have to mention the results from a study indi-
cating a potent inhibitory effect of 9-phenanthrol, with other
phenanthrene derivatives, on bovine heart cyclic-AMP-
dependent PKA catalytic subunits (Wang et al., 1994).
However, the experiments were only conducted in vitro by
biochemical assays of the reaction medium, and this inhibi-
tory effect on PKA catalytic subunits has not been demon-
strated in model cells of native tissues. To the best of our
knowledge, this biochemical experiment from the 1990s has
never been repeated or confirmed. On the contrary, the
effects of 9-phenanthrol in cardiac preparations were not
precluded by the simultaneous application of the PKA inhibi-
tor H-89, which argues against an effect of 9-phenanthrol via
PKA inhibition (Simard et al., 2012a; 2013).
Altogether, these results indicate that 9-phenanthrol is a
selective TRPM4 channel inhibitor. Nonetheless, as shown in
cardiomyocytes, some side effects may be observed at con-
centrations at or exceeding 10−4 mol·L−1.
Smooth muscle cell contraction
Identifying 9-phenanthrol as a TRPM4 channel-specific
inhibitor has provided the opportunity to distinguish TRPM4
currents from currents evoked through TRPM5 and it has
provided a powerful tool to reveal the role(s) of TRPM4 chan-
nels in physiological processes. Through its modulation of
TRPM4 channels, 9-phenanthrol affects smooth muscle
behaviour, spontaneous firing in neurons and cardiomyo-
cytes, as well as protecting against cardiac or vascular injuries
(see later and Table 3).
A preliminary series of studies focused on arterial smooth
muscles that are known to express TRPM4 (Earley, 2013).
Arteries respond to pressure overload by a vasoconstriction in
order to autoregulate blood flow. In an experimental model of
isolated cerebral arteries from rat, 9-phenanthrol dilated
arteries that were previously pressurized (Gonzales et al.,
2010b). This occurred with an EC50 of 2.6 × 10−6 mol·L−1 indi-
cating a high sensitivity to 9-phenanthrol. Interestingly,
down-regulation of Trpm4 expression using antisense oligo-
deoxynucleoides also affected vasoconstriction in this prepa-
ration, which further implicates the TRPM4 channel in this
tissue (Earley et al., 2004). Arterial contraction requires L-type
Ca2+ current activation. Thus, control of membrane potential
is a critical factor that influences the phenomenon. Using
intracellular microelectrode recordings, 3 × 10−5 mol·L−1
9-phenanthrol was shown to hyperpolarize vascular smooth
muscle cells in pressurized cerebral arteries. The mechanism
of action probably involves the inhibition of a TRPM4-
depolarizing current via a mechanism explained later
(Gonzales et al., 2010b). 9-Phenanthrol was also shown to
inhibit a depolarizing transient inward cationic current in the
same preparation; this effect was prevented if the cells were
treated with Trpm4 small interfering RNA (Gonzales et al.,
2010a; Gonzales and Earley, 2012). The putative mechanism
for vasoconstriction of cerebral arteries in response to
pressure-dilatation involves a mechanosensitive membrane
protein coupled to PLC, whose activation produces inositol
1,4,5-trisphosphate (IP3). IP3 binds to its receptor on the sar-
coplasmic reticulum to induce calcium release and thus
TRPM4 channel activation ensues. The TRPM4 channel is an
inward charge carrier (with a reversal potential ∼0 mV) that
induces cell depolarization in favour of L-type Ca2+ current
activation, producing inward Ca2+ currents and cell contrac-
tion (Earley, 2013). The phenomenon also depends on PKC to
promote translocation of TRPM4 channels to the plasma
membrane. Small interfering Trpm4 RNA or treatment with
2 × 10−5 mol·L−1 9-phenanthrol similarly abolish the PKC-
induced cerebral artery vasoconstriction (Crnich et al., 2010).
Cerebral artery pressure-induced constriction involves
sphingosine-kinase-1 translocation from the cytosol to the
plasma membrane, which produces sphingosine-1-phosphate
following membrane depolarization. In an experimental
model of rabbit posterior cerebral arteries, 5 × 10−6 mol·L−1
9-phenanthrol attenuated this pressure-induced transloca-
tion (Lim et al., 2012).
Among smooth muscles that express the TRPM4 channel,
an effect of 9-phenanthrol was also demonstrated in DSM
that controls urinary bladder contraction. The expression
level of Trpm4 mRNA is 2.6-fold greater in DSM cells than in
cerebral artery myocytes (Parajuli et al., 2013). The intracel-
lular signalling that leads to DSM contraction remains to be
determined, but it may resemble the one described earlier for
cerebral arteries. Variations in the intracellular Ca2+ concen-
trations activate a transient inward cationic current that is
consistent with an NSCCa. This inward current causes cell
membrane depolarization, inducing L-type Ca2+ current acti-
vation, which leads to significant accumulation of intracellu-
lar Ca2+ that then stimulates contraction (Smith et al., 2013b).
9-Phenanthrol affects several of these parameters in DSM.
The transient inward cationic current with TRPM4-like prop-
erties was inhibited by 3 × 10−5 mol·L−1 9-phenanthrol in both
BJPThe TRPM4 inhibitor 9-phenanthrol
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rat and guinea pig freshly isolated DSM cells (Smith et al.,
2013a,b). The same concentration of 9-phenanthrol also
reduced the baseline intracellular Ca2+ level measured by Ca2+-
sensitive fluorescent dyes (Smith et al., 2013a). Because this
effect on baseline Ca2+ is reduced by nifedipine, but not by
carbachol, it is attributed to a decrease in Ca2+ influx via
L-type channels subsequent to a decrease in channel activa-
tion due to the lack of membrane depolarization (Smith
et al., 2013a). Contractions of the DSM are also affected by
9-phenanthrol. Whereas pharmacological tools such as car-
bachol increase basal tension and spontaneous contractions,
9-phenanthrol reduces the force, amplitude and frequency
of carbachol-induced contractions from rat isolated DSM
strips with an IC50 ranging from 1.7 to 3.3 × 10−6 mol·L−1
(Smith et al., 2013b). DSMs are activated by parasym-
pathetic inputs that induce bladder voiding behaviour. This
neurogenic control can be mimicked by electrical field stimu-
lation, which induces DSM strips to contract. During such
recordings, 9-phenanthrol attenuates the amplitude of the
contraction and muscle force with an IC50 of 2.3 and
2.8 × 10−6 mol·L−1 respectively (Smith et al., 2013b). These
results obtained using 9-phenanthrol indicate that the
TRPM4 channel is a major contributor to excitation–
contraction coupling in the DSM.
Membrane current regulation has also been demonstrated
in smooth muscle cells of the colon. The resting membrane
potential is generally less negative than the K+ equilibrium
potential as a result of a spontaneous inward current with
non-selective cation permeability, which shares single-
channel properties with TRPM4 (Dwyer et al., 2011). In
freshly dispersed colonic smooth muscle cells from monkeys,
this TRPM4-like current is inhibited by 10−4 mol·L−1 9-
phenanthrol. No further experiments were conducted using
9-phenanthrol in this preparation, even though the authors
demonstrated that La3+ and Gd3+ both modulated the baseline
membrane potential, presumably by attenuating the same
TRPM4-like current (Dwyer et al., 2011).
Modulation of heart function
Investigating the role of the TRPM4 channel in cardiac physi-
ology and pathophysiology is of great importance, firstly,
because the heart is among the foremost TRPM4-expressing
tissues (Launay et al., 2002) and secondly, because the only
known channelopathy related to TRPM4 dysfunction in
humans perturbs cardiac electrical activity: for example, con-
genital conduction block and Brugada syndrome (Kruse et al.,
2009; Liu et al., 2010; 2013). Endogenous TRPM4-like cur-
rents have been thoroughly characterized in cardiac prepara-
tions (see review, Guinamard et al., 2011), but demonstrating
their specific roles in cardiac tissues has only become possible
following the discovery of 9-phenanthrol as a TRPM4
channel inhibitor. 9-Phenanthrol revealed the roles of the
TRPM4 channel in both basal cardiac activity and in
pathological-like conditions.
Cardiac rhythm initiates in the specific pacemaker tissue
dubbed the sinoatrial node at the flank of the right atrium.
Intracellular microelectrodes can record spontaneous activity
of isolated right atrium preparations suspended in a super-
fusion bath. The rate of spontaneous action potentials
from mouse and rat preparations is reversibly reduced by
Table 3
Effects of 9-phenanthrol on physiological processes
Physiological processes Model Effect
Concentration
in mol·L−1 References
Artery constriction Rat cerebral arteries Inhibition IC50 = 2.6 × 10−6 Gonzales et al., 2010b
Smooth muscle contraction Rat, guinea pig isolated detrusor
muscle
Inhibition IC50 = 3 × 10−6 Parajuli et al., 2013; Smith
et al., 2013a,b
Cardiac beating rate Mouse, rat, rabbit isolated right
atrium
Reduction EC50 = 7.8 × 10−6 Hof et al., 2013
Cardiac atrial action potential
duration
Mouse isolated atrium Reduction EC50 = 2.2 × 10−5 Simard et al., 2013
Hypoxia-reoxygenation induced
cardiac arrhythmias
Mouse isolated ventricle Reduction 60%
Reduction 100%
10−5
10−4
Simard et al., 2012a
Hypoxia-reoxygenation
preconditioning
Rat isolated whole heart Cardioprotection 3 × 10−5 Wang et al., 2013
LPS-induced cell death Endothelial cells HUVECs Reduction 50% 10−6 Becerra et al., 2011
Cell viability Adrenocarcinoma cells AGS and
MKN-45
None 3 × 10−5 Kim et al., 2012
Capillary structure formation Endothelial cells HUVECs Stimulation 5 × 10−6 Loh et al., 2013
Neuronal bursting activity Mice coronal midbrain slice Reduction 10−4 Mrejeru et al., 2011
Neuronal firing activity Mice olfactory bulb slice Reduction 50% 10−4 Shpak et al., 2012
Neuronal firing activity Rat inhibitory prepositus
hypoglossy nucleus neurons
Reduction 60% 10−4 Saito and Yanagawa, 2013
When known, the IC50 is presented, otherwise, the concentration tested is indicated with the corresponding % of reduction.
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9-phenanthrol with an IC50 of 7.8 × 10−6 mol·L−1 (Figure 3;
Hof et al., 2013). A particular characteristic of sinoatrial node
cells is the presence of a slow diastolic depolarization (absent
in other cardiac myocytes) that drives the membrane poten-
tial over the threshold for Ca2+ current activation, and is
responsible for the action potential upstroke. While a major
part of this slow diastolic depolarization is due to the
hyperpolarization-activated funny current (If) (Monfredi
et al., 2010), which is equivalent to Ih in neurons, an addi-
tional component of the slow diastolic depolarization is due
to Ca2+-activated depolarizing currents triggered by cytoplas-
mic Ca2+ oscillations. In the rabbit isolated sinoatrial node,
10−5 mol·L−1 9-phenanthrol reduces both the beating rate
and the slope of the slow diastolic depolarization, with no
other effects on sinoatrial node action potentials. This
9-phenanthrol-induced reduction in sinoatrial node beating
rate is absent in Trpm4−/− mice (Hof et al., 2013) and TRPM4
currents were characterized in isolated sinoatrial node cells
from wild-type mice (Demion et al., 2007), which clearly
demonstrates that the TRPM4 channel is involved in
regulating the rate of beating. Interestingly, the ability of
9-phenanthrol to reduce the beating rate in mouse and rat
isolated right atrium is more pronounced at low frequencies
(Hof et al., 2013), which suggests that the TRPM4 channel
could protect against bradycardia and, this might be modu-
lated by 9-phenanthrol.
The results summarized earlier indicate that 9-
phenanthrol acts in sinoatrial node cells to directly slow the
diastolic depolarization through inhibiton of TRPM4 chan-
nels. However, a study conducted on the HL-1 cell line
derived from mouse atrial cells revealed that 9-phenanthrol
also modulates cytoplasmic calcium oscillations (Burt et al.,
2013). HL-1 cells are derived from atrial cardiomyocytes, but
not specifically sinoatrial node cells, and they acquire prop-
erties similar to those of pacemaker cells and develop free
beating activity, with intracellular calcium oscillations being
present in about 40% of the cells (Wondergem et al., 2010).
Fluorescent Ca2+ recordings using Fura-2 revealed that
10−5 mol·L−1 9-phenanthrol abolishes these Ca2+ oscillations
leading to a transient increase in cytoplasmic Ca2+, attributed
to the release of Ca2+ from an intracellular pool different from
the sarcoplasmic reticulum and thus, is most likely to be
mitochondrial Ca2+ (Burt et al., 2013). These Ca2+ oscillations
could participate in the spontaneous activity, since the appli-
cation of 10−5 mol·L−1 9-phenanthrol in cell-attached record-
ings from HL-1 cells abolished the depolarizing inward ionic
currents that contribute to the slow diastolic depolarization
(Burt et al., 2013).
In addition to its effect on spontaneous beating, 9-
phenanthrol also modulates action potentials evoked in
mouse atrial cardiomyocytes; recorded using intracellular
microelectrodes. 9-Phenanthrol reduced action potential
duration, with an IC50 of 2.2 × 10−5 mol·L−1, without affecting
other action potential parameters or the resting membrane
potential (Simard et al., 2013). This effect of 9-phenanthrol
on action potential duration is probably as a results of its
inhibitory effect on TRPM4 channels because (i) a TRPM4
current can be recorded from mouse isolated atrial cells and
this endogenous current is inhibited by 9-phenanthrol
(Simard et al., 2013); (ii) the effect of 9-phenanthrol is
strongly reduced in ventricular tissue, which is known to
express lower levels of the TRPM4 channel compared with
the atrium (Guinamard et al., 2006; Liu et al., 2010; Simard
et al., 2013); and (iii) the 9-phenanthrol effect is completely
absent in atria from Trpm4−/− mice (Simard et al., 2013). While
these experiments were done in mice, their relevance prob-
ably extends to humans as human isolated atrial cardiomyo-
cytes have been reported to express functional TRPM4
channels (Guinamard et al., 2004).
9-Phenanthrol does not only modulate basal cardiac
activity, but has also been shown to prevent cardiac dysfunc-
tion induced by ischaemia-reperfusion episodes. Ischaemia,
such as that observed in coronary occlusion, is a major source
of cardiac damage. It produces electrical perturbations that
lead to arrhythmias, it decreases contractility and it induces
apoptosis. Although it corrects oxygen defects, reperfusion
paradoxically exacerbates ischaemia-related perturbations,
mainly through disturbance of internal Ca2+ homeostasis
(Murphy and Steenbergen, 2008). As the TRPM4 channel is
an ATP-sensitive Ca2+-activated channel and because it is
highly expressed in heart, it was thought to be involved
in ischaemia-related perturbations. Therefore, the TRPM4
channel inhibitor 9-phenanthrol was tested for possible car-
dioprotective effects. In an initial study, the effect of
9-phenanthrol against arrhythmias was investigated in a
Figure 3
Effects of 9-phenanthrol on heart rhythm in a mouse isolated right
atrium. Spontaneous action potentials were recorded using an intra-
cellular microelectrode, while the right isolated atrium was super-
fused with oxygenated physiological solution. (A) Time course of the
effect of 10−4 mol·L−1 9-phenanthrol on beating rate measured every
10 s as beats min-1 (bpm). The application of 9-phenanthrol is indi-
cated by the grey shading. Note that the effects of 9-phenanthrol
were reversible. (B) Representative recordings for control,
9-phenanthrol, and washout, as indicated in (A) by arrows. See Hof
et al. (2013) for protocols.
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mouse isolated ventricle subjected to hypoxia-reoxygenation
protocols, in order to mimic ischaemia-reperfusion condi-
tions (Simard et al., 2012a). During hypoxia, as well as during
reoxygenation, arrhythmias were observed in the form of
early after depolarizations (EADs). Superfusion of 10−5 mol·L−1
9-phenanthrol during reoxygenation reduced the occurrence
of EADs by 60% while 10−4 mol·L−1 totally abolished the EADs
(Simard et al., 2012a). Figure 4 shows an example of such
anti-arrhythmic effects in ventricular myocytes. As in the
atrial tissue, 9-phenanthrol does not regulate the resting
membrane potential at the ventricular level. In this model, it
was hypothesized that EADs were formed in the conductive
tissue such as Purkinje fibres, where TRPM4 channels are
highly expressed (Liu et al., 2010), and were transmitted to
the ventricular cells. In a second study, the cardioprotective
effect of 9-phenanthrol was tested in a rat isolated whole
heart perfused using a Langendorff apparatus (Wang et al.,
2013). Ischaemia-reperfusion was mimicked by switching off
and on the perfusion of physiological solution in the coro-
nary vessels. The preconditioning effect of 2 × 10−5 mol·L−1
9-phenanthrol was tested by applying the drug 3 min before
a 30 min ischaemia episode, which was then followed by
reperfusion. 9-Phenanthrol prevented the decrease in con-
tractile function, and the occurrence of ventricular fibrilla-
tion or tachycardia. In addition, as a proof of prophylaxis
against cellular damage, 9-phenanthrol reduced lactate
dehydrogenase activity and the size of the infarcted area
(Wang et al., 2013). As this effect of 9-phenanthrol was not
prevented by addition of the ATP-sensitive K+ channel inhibi-
tor 5-hydroxydecanoate, its effects were attributed to the
TRPM4 channel inhibition (Wang et al., 2013). These two
complementary studies revealed 9-phenanthrol to be a new
and potentially powerful cardioprotective agent against
ischaemia-reperfusion injuries. The rapid kinetics of 9-
phenanthrol’s antiarrhythmic effects is consistent with the
direct involvement of the TRPM4 channel in cardiac action
potentials (Simard et al., 2012a). Inversely, the slow kinetics
of 9-phenanthrol in the preconditioning model suggests an
additional subcellular process subsequent to TRPM4 channel
inhibition (Wang et al., 2013).
Prevention of cell death
The TRPM4 channel is involved to some extent in cell death
(Schattling et al., 2012; Simard et al., 2012b). Oxidative stress
induces HeLa cell death by necrosis, but not apoptosis,
through TRPM4 channel activation (Simon et al., 2010). The
effect of 9-phenanthrol on this process was investigated in a
model of HUVECs, which endogenously express TRPM4
channels, but not TRPM5 channels (Becerra et al., 2011). In
those cells, LPS induces cell death by promoting Na+ overload
leading to cell depolarization and cell volume increase. LPS-
induced cell death was estimated by lactate dehydrogenase
release, thiazolyl blue tetrazolium bromide (MTT) salt colori-
metric assay and trypan blue. Treatment with 10−6 mol·L−1
9-phenanthrol reduced cell death by half (Becerra et al.,
2011). These protective effects of 9-phenanthrol were repro-
duced by glibenclamide (Becerra et al., 2011), which is also
known to inhibit the TRPM4 channel (Demion et al., 2007).
The LPS-induced Na+-current is inhibited by glibenclamide, as
expected, but the effect of 9-phenanthrol on this current was
not tested (Becerra et al., 2011). Note that in control condi-
tions 9-phenanthrol at concentrations ranging from 10−7 to
5 × 10−6 mol·L−1 does not induce cell death in HUVECs,
although higher concentrations may have deleterious effects
(Loh et al., 2013).
The prophylactic effect of 9-phenanthrol observed in
HUVECs is probably not a widespread phenomenon, as appli-
cation of 9-phenanthrol, even at 4 × 10−5 mol·L−1 does not
protect the H9c2 cardiomyocyte cell line against peroxide-
induced damage (Wang et al., 2013).
Figure 4
Cardioprotective effect of 9-phenanthrol. Anti-arrhythmic effects of 9-phenanthrol in a model of hypoxia-reoxygenation induced arrhythmias in
mouse isolated ventricle. An isolated right ventricle was submitted to a hypoxic episode and then reoxygenated, which induces EADs. In this
model, spontaneous beating was thought to arise from Purkinje fibres. (A) Time course of the effects of 10−4 mol·L−1 9-phenanthrol on the
occurrence of EADs. The number of EADs was measured in successive 10 s windows. The application of 9-phenanthrol is indicated by the grey
shading. Note the total and reversible abolition of arrhythmias after the application of 9-phenanthrol. (B) Representative recordings for control,
9-phenanthrol and washout. While several EADs were present in one-fifth of the action potentials in control, the rhythm was perfectly regular in
the presence of 9-phenanthrol. See Simard et al. (2012a) for protocols.
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The effects of 9-phenanthrol, at 1, 2 and 3 × 10−5 mol·L−1,
on cell viability were investigated in human gastric adeno-
carcinoma cell lines AGS and MKN-45 by use of the MTT
colorimetric assay. None of these concentrations affected cell
viability (Kim et al., 2012).
Stimulation of angiogenesis after
ischaemic stroke
Ischaemic stroke increases an ATP-sensitive NSCCa current in
neurovascular cells and neuroendothelia (Simard et al., 2006).
This current is supported by a combination of SUR-1 and the
TRPM4 channel, whose activation leads to oncotic death of
endothelial cells and consequently, capillary fragmentation
(Simard et al., 2010; Woo et al., 2013b). Ischaemic stroke con-
ditions were mimicked in cultures of HUVECs by incubating
the cells in a hypoxic solution and depriving them of glucose
and serum (Loh et al., 2013). Such deprivation increases cell
death after 24 h. While 5 × 10−6 mol·L−1 9-phenanthrol did
not reduce cell death, it did promote the formation of capil-
lary structures on Matrigel, as detected by light microscopy
(Loh et al., 2013). This effect was attributed to TRPM4
channel inhibition because 24 h of oxygen and glucose dep-
rivation produces TRPM4 overexpression at the mRNA and
protein level and activates a TRPM4-like current that is inhib-
ited by 10−4 mol·L−1 9-phenanthrol (Loh et al., 2013). These
results show that 9-phenanthrol, via TRPM4 channel inhibi-
tion, improves the functionality of endothelial cells under
conditions that mimic ischaemic stroke.
Modulation of neuronal activity
9-Phenanthrol modulates electrical activity in neurons and
neural systems. NSCCa current with the hallmarks of the
TRPM4 channel are present in the CNS where they participate
in generating bursting activity in networks such as the
breathing-related rhythmogenic neurons from the pre-
Bötzinger complex (Pace et al., 2007; Mironov, 2008; Mironov
and Skorova, 2011) and in neurons of the substantia nigra
pars compacta (Mrejeru et al., 2011). Glutamate receptor acti-
vation gives rise to cytoplasmic Ca2+ that activates the depo-
larizing NSCCa current, favouring rhythmic burst generation.
The effect of 9-phenanthrol on this activity was tested in a
coronal midbrain slice model from juvenile mice. Electrical
bursting in nigrostriatal dopamine-releasing neurons was
recorded under NMDA stimulation. Burst frequency was
reversibly reduced by 10−4 mol·L−1 9-phenanthrol, which
changed the burst-firing pattern into one characterized by
tonic firing (Mrejeru et al., 2011).
Accessory olfactory bulb neurons involved in transmit-
ting pheromonal stimuli also express Trpm4 mRNA and
exhibit a TRPM4-like current activated by afferent sensory
fibre stimulation. In mice brain slices, inhibition of this
current by 10−4 mol·L−1 9-phenanthrol reduces their ability
to discharge repetitively (i.e. persistent firing) (Shpak et al.,
2012).
The prepositus hypoglossi nucleus of the brainstem is
involved in maintaining horizontal gaze. Inhibitory neurons
from this structure exhibit NSCCa channels (Saito and
Yanagawa, 2010). In slice preparations from the rabbit brain-
stem, 10−4 mol·L−1 9-phenanthrol was shown to reduce firing
rate by 60% in these neurons (Saito and Yanagawa, 2010;
2013).
The appropriate use of 9-phenanthrol in
physiological studies
Our meta-analysis of the studies presented earlier suggests
that 9-phenanthrol modulates physiological processes
mainly through TRPM4 channel inhibition. (i) In most
models, the drug reduces an NSCCa in Trpm4-expressing cells
(Gonzales et al., 2010a; Simard et al., 2013; Smith et al.,
2013a,b). (ii) When tested, the effect of 9-phenanthrol is not
reproduced in Trpm4–/– mice (Hof et al., 2013; Simard et al.,
2013) or its effects can be mimicked by small interfering
Trpm4 RNA treatment (Crnich et al., 2010). (iii) The IC50
values for the effects of 9-phenanthrol on physiological pro-
cesses are in the same range as those measured for TRPM4
channel inhibition in recombinant HEK cells (Tables 1–3).
(iv) The effect of 9-phenanthrol can be reproduced by other
TRPM4 inhibitors such as flufenamic acid (Gonzales et al.,
2010a; Saito and Yanagawa, 2010; Mrejeru et al., 2011; Shpak
et al., 2012; Simard et al., 2012a; 2013; Amarouch et al., 2013;
Burt et al., 2013; Kim et al., 2013) and glibenclamide (Becerra
et al., 2011; Kim et al., 2013).
We conclude that 9-phenanthrol can confidently be used
as a specific TRPM4 channel inhibitor. Nevertheless, high
concentrations (at or exceeding 10−4 mol·L−1) must be used
with caution for several reasons.
Firstly, 9-phenanthrol may precipitate at high concentra-
tions, thus the final diluted concentration may be overesti-
mated. 9-Phenanthrol is usually diluted in DMSO in a stock
solution at 10−1 mol·L−1 and then diluted in the physiological
perfusion solution, such that the maximal DMSO ratio of
0.01% is not exceeded even when the final concentration
of 9-phenanthrol reaches 10−4 mol·L−1. This concentration of
DMSO in the bathing solution has no effect on the TRPM4
channel (Grand et al., 2008). Because 9-phenanthrol partly
precipitates at higher concentrations, one can increase the
final DMSO concentration if a relatively high concentration
of 9-phenanthrol is called for. Nevertheless, in general, this
use of DMSO should be avoided because a high concentration
of DMSO may introduce new side effects. DMSO inhibits
non-selective cation channels such as NMDA and AMPA glu-
tamate receptors when used at or above 0.5% (Lu and
Mattson, 2001), and it inhibits whole-cell non-selective cati-
onic currents in erythrocytes at or above 1% (Nardid et al.,
2013).
Secondly, in rat cardiomyocytes, 10−4 mol·L−1 9-
phenanthrol affects both L-type Ca2+ currents and delayed
outward rectifier K+ currents (Simard et al., 2012a). Even if
these effects on active membrane properties do not explain
the modulation of electrical activity by 9-phenanthrol in
cardiomyocytes, the effects on Ca2+ and K+ channels must to
be considered carefully because of the ubiquity and wide-
spread influence of these channels on voltage trajectory and
intracellular signalling in many types of excitable cells.
Thirdly, 9-phenanthrol autofluoresces under UV light
(Moriconi et al., 1959) in particular at 340 nm, which can
induce artefacts when measuring Ca2+ or voltage using fluo-
rescent dyes (Burt et al., 2013). This can cause problems when
using high concentrations.
Fourthly, while the effects of 9-phenanthrol are revers-
ible in most studies, the recovery is more problematic at
10−4 mol·L−1, which is probably due to the accumulation
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of 9-phenanthrol in membranes, because of its high
hydrophobicity.
The most appropriate concentrations of 9-phenanthrol
for physiological studies range from 1 × 10−5 to 3 ×
10−5 mol·L−1. The lower limit corresponds closely to the IC50
for TRPM4 channel inhibition, while the upper limit pro-
duces an 80% inhibition of the current. The 3 × 10−5 mol·L−1
upper limit is sufficient to strongly affect recombinant
TRPM4 current (Grand et al., 2008) as well as physiological
processes, and perhaps more importantly, is devoid of side
effects. Although several studies have demonstrated the
physiological effects of 9-phenanthrol, they are less apparent
at lower concentrations.
Note that, while 9-phenanthrol dissolved in DMSO can be
stored at −20°C, it degrades with time. We would thus rec-
ommend that once it is in solution it should be used within
a month.
9-Phenanthrol, a TRPM4 channel inhibitor
for what purpose?
Our reading and laboratory experience indicates that
9-phenanthrol is an appropriate tool to investigate the func-
tional significance of the TRPM4 channel in physiological
and pathological processes. The drug is suitable for a variety
of physiological approaches such as: (i) electrophysiological
recordings using patch-clamp pipettes in single-channel
or whole-cell configurations; (ii) transmembrane potential
recording in multicellular preparations using an intracellular
microelectrode; (iii) calcium measurements by fluorescent
dyes; (iv) measurements of smooth muscle contraction; and
(v) cell culture (which is amenable to the same set of meas-
uring tools listed earlier).
A particular strength of 9-phenanthrol is its ability to
distinguish TRPM4 from TRPM5 channels, which are other-
wise quite similar (Ullrich et al., 2005; Guinamard et al.,
2011). Because these two ion channels hold ionic currents
with similar properties, the discovery of 9-phenanthrol has
provided a convenient tool to differentiate one from the
other in native preparations. A variety of NSCCa reported in
native cells remain to be identified at the molecular level.
9-Phenanthrol thus might help resolve whether the underly-
ing channels are TRPM4, TRPM5, or another variety of TRP
channel. This issue is especially relevant in kidney tissue,
which is known to express high levels of Trpm4 mRNA
(Launay et al., 2002) and a native NSCCa current, whose iden-
tity is still not known (Chraïbi et al., 1994; Teulon, 2000).
This disparity also applies for neurons of the pre-Bötzinger
complex that express both Trpm4 and Trpm5 mRNA, and a
NSCCa current implicated in rhythmic cellular and network
bursting that serves to generate inspiratory breathing move-
ments (Crowder et al., 2007; Pace et al., 2007; Mironov, 2008;
Mironov and Skorova, 2011).
The TRPM4 channel has already been shown to be
involved in a variety of physiological processes, such as cer-
ebral artery constriction (Earley, 2013), insulin secretion by
pancreatic beta cells (Cheng et al., 2007), immune responses
(Launay et al., 2004; Vennekens et al., 2007; Barbet et al.,
2008), DSM contraction (Smith et al., 2013a,b) and cardiac
action potentials (Hof et al., 2013; Simard et al., 2013).
Moreover, the channel is implicated in pathologies such as
autoimmune encephalomyelitis (Schattling et al., 2012),
ischaemia and ischaemia-reperfusion injuries in the brain or
the heart (Simard et al., 2012a; Loh et al., 2013), cardiac
hypertrophy (Guinamard et al., 2006), as well as human
cardiac-genetic diseases (Kruse et al., 2009; Liu et al., 2010;
2013). It is tempting to speculate that 9-phenanthrol,
through its effects on TRPM4 current, may modulate such
pathological processes and could potentially ameliorate or
correct their perturbations. This has already been observed in
several studies, as described earlier. By modulating cardiac
rhythm, 9-phenanthrol might function as a bradycardic
agent (Hof et al., 2013). Also, as it reduces cardiac injuries
induced by hypoxia-reoxygenation 9-phenanthrol may have
cardioprotective properties (Simard et al., 2012a; Wang et al.,
2013). By promoting angiogenesis, the drug may inhibit cer-
ebral oedema damage after ischaemic stroke (Loh et al.,
2013). Its inhibitory effect on the detrusor muscle might
mean it has potential as a drug for the treatment of overactive
bladder (Smith et al., 2013a,b). By preventing LPS-induced
endothelial cell death, 9-phenanthrol may benefit the treat-
ment of endotoxaemia-derived sepsis (Becerra et al., 2011).
However, while these possibilities are exciting and provoca-
tive, it is still too early to predict specific clinical applications
because all of the studies reviewed earlier were performed in
vitro or on isolated cells or tissues. Among the barriers that
must be overcome before going further in that direction is the
ability to reach the sufficiently high levels of circulating drug
in vivo to inhibit the TRPM4 channel. In that regard, the low
solubility of 9-phenanthrol might be an obstacle. In addition,
the toxicity of 9-phenanthrol has to be carefully evaluated as
PAH are known to have consistent toxic effects (Feng et al.,
2012). This last point was highlighted by results from a very
recent study using in vitro biochemical assays, which indi-
cated that 9-phenanthrol inhibits the biosynthesis of andro-
gen and oestrogen in subcellular fractions of carp gonads
(Fernandes and Porte, 2013).
Conclusion
The identification of 9-phenanthrol as a TRPM4 channel
inhibitor opens up new ways to discover the role(s) of the
TRPM4 channel and provides a specific and potent pharma-
cological tool to examine the ion channel-level mechanisms
underlying physiological and pathophysiological processes.
The applicability of this molecule or related drugs for thera-
peutic purposes is a new prospect that remains to be explored.
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